Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.

Published on Nov 2, 2020in Cancer Science
· DOI :10.1111/CAS.14686
Kazuyoshi Kumagai7
Estimated H-index: 7
(Daiichi Sankyo),
Tetsuo Aida6
Estimated H-index: 6
(Daiichi Sankyo)
+ 3 AuthorsKazuhiko Mori9
Estimated H-index: 9
(Daiichi Sankyo)
Trastuzumab deruxtecan (T-DXd: DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) Ab-drug conjugated with deruxtecan (DXd), a derivative of exatecan. The objective of this study was to characterize T-DXd-induced lung toxicity in cynomolgus monkeys. Trastuzumab deruxtecan was injected i.v. into monkeys once every 3 weeks for 6 weeks (10, 30, and 78.8 mg/kg) or for 3 months (3, 10, and 30 mg/kg). To evaluate the involvement of DXd alone in T-DXd-induced toxicity, DXd monohydrate was given i.v. to monkeys once a week for 4 weeks (1, 3, and 12 mg/kg). Interstitial pneumonitis was observed in monkeys given T-DXd at 30 mg/kg or more. The histopathological features of diffuse lymphocytic infiltrates and slight fibrosis were similar to interstitial lung diseases (ILD)/pneumonitis related to anticancer drugs in patients, with an incidence that was dose-dependent and dose-frequency-dependent. Monkeys receiving DXd monohydrate did not suffer lung toxicity, although the DXd exposure level was higher than that of DXd in the monkeys given T-DXd. The HER2 expression in monkey lungs was limited to the bronchial level, although the lesions were found at the alveolar level. Immunohistochemical analysis confirmed that T-DXd localization was mainly in alveolar macrophages, but not pulmonary epithelial cells. These findings indicate that monkeys are an appropriate model for investigating T-DXd-related ILD/pneumonitis. The results are also valuable for hypothesis generation regarding the possible mechanism of T-DXd-induced ILD/pneumonitis in which target-independent uptake of T-DXd into alveolar macrophages could be involved. Further evaluation is necessary to clarify the mechanism of ILD/pneumonitis in patients with T-DXd therapy.
📖 Papers frequently viewed together
2 Citations
277 Citations
14 Authors (Yung-Jue Bang, ..., H. A. Burris)
80 Citations
#1Junji Tsurutani (Kindai University)H-Index: 34
#2Hiroji IwataH-Index: 72
Last. Bob T. Li (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 33
view all 16 authors...
HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers. We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC ≥ 1+), non-breast/non-gastric or HER2-mutant solid tumors from a phase I trial (NCT02564900). Most common (>50%) treatment-emergent adverse events (TEAE) were nausea, decreased appetite, and vomiting. Two drug-related TEAEs were...
30 CitationsSource
#1Yoshiaki Zaizen (Nagasaki University)H-Index: 3
#2Junya Fukuoka (Nagasaki University)H-Index: 40
This review discusses diagnostic pathology in idiopathic interstitial pneumonias (IIPs). Accurate understanding of basic structure of lung lobules is critical because the location of abnormalities inside the lobule is an important effector of pathology diagnosis. Depending on the method of obtaining tissue, recognition of the location may be difficult or impossible. Cryobiopsy is a new technology and its coverage of lung lobules is limited. This article discusses fundamental anatomy and approach...
2 CitationsSource
#1Shanu Modi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 46
#2Cristina SauraH-Index: 33
Last. Ian E. KropH-Index: 77
view all 25 authors...
Abstract Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linke...
207 CitationsSource
#1Do Youn Oh (SNU: Seoul National University)
#1Do-Youn Oh (New Generation University College)H-Index: 30
Last. Yung-Jue Bang (SNU: Seoul National University)H-Index: 107
view all 2 authors...
HER2 is an established therapeutic target in a large subset of women with breast cancer; a variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1) have been approved for the treatment of HER2-positive breast cancer. HER2 is also overexpressed in subsets of patients with other solid tumours. Notably, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric cancer, and has bec...
89 CitationsSource
#1Takashi OguraH-Index: 55
#2Nagio Takigawa (Kawasaki Medical School)H-Index: 46
Last. DldH-Index: 1
view all 43 authors...
Abstract Dramatic progress in targeted therapy and immunotherapy has been changing clinical practices in lung cancer. With the accumulation of clinical practice, it has become clear that pre-existing interstitial pneumonia (IP) could be a risk factor for drug-induced lung injury, which has enhanced awareness regarding the difficulty in treating lung cancer with comorbid IP. Unfortunately, there is only low-grade evidence in the field of lung cancer with comorbid IP, because almost all clinical t...
8 CitationsSource
#1Takashi Shiina (Tokai University)H-Index: 28
#2Antoine Blancher (French Institute of Health and Medical Research)H-Index: 6
Among the non-human primates used in experimental medicine, cynomolgus macaques (Macaca fascicularis hereafter referred to as Mafa) are increasingly selected for the ease with which they are maintained and bred in captivity. Macaques belong to Old World monkeys and are phylogenetically much closer to humans than rodents, which are still the most frequently used animal model. Our understanding of the Mafa genome has progressed rapidly in recent years and has greatly benefited from the latest tech...
10 CitationsSource
ABSTRACT Antibody-drug conjugates (ADCs) are a promising therapeutic modality for oncology indications. The concept of an ADC platform is to increase the therapeutic index (TI) of chemotherapeutics through more selective delivery of cytotoxic agents to tumor cells while limiting exposure to healthy normal cells. Despite the use of antibodies targeting antigens abundantly and/or exclusively expressed on cancer cells (i.e., target cells), dose limiting toxicities (DLTs) in normal cells/tissues are...
15 CitationsSource
Antibodies and Fc-fusion antibody-like proteins have become successful antibody-based biologics developed for cancer treatment, passive immunity against infection, addiction, and autoimmune diseases. In general these biopharmaceuticals can be used for blocking protein:protein interactions, crosslinking host receptors to induce signaling, recruiting effector cells to targets, and fixing complement. With the vast capability of antibodies to affect infectious and genetic diseases much effort has be...
56 CitationsSource
#1Takashi Nakada (Daiichi Sankyo)H-Index: 5
#2Kiyoshi Sugihara (Daiichi Sankyo)H-Index: 4
Last. Toshinori Agatsuma (Daiichi Sankyo)H-Index: 12
view all 5 authors...
: A major limitation of traditional chemotherapy for cancer is dose-limiting toxicity, caused by the exposure of non-tumor cells to cytotoxic agents. Use of molecular targeted drugs, such as specific kinase inhibitors and monoclonal antibodies, is a possible solution to overcome this limitation and has achieved clinical success so far. Use of an antibody-drug conjugate (ADC) is a rational strategy for improving efficacy and reducing systemic adverse events. ADCs use antibodies selectively to del...
48 CitationsSource
#1Yoko Nagai (Daiichi Sankyo)H-Index: 8
#2Masataka Oitate (Daiichi Sankyo)H-Index: 10
Last. Osamu Ando (Daiichi Sankyo)H-Index: 16
view all 4 authors...
AbstractTrastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) conjugated to a topoisomerase I inhibitor (DXd) at a drug-to-antibody ratio (DAR) of 7-8. Here, we examined the pharmacokinetic (PK) profiles of DS-8201a and DXd in cynomolgus monkeys, a cross-reactive species.Following intravenous (iv) administration of DS-8201a, the linker was stable in plasma, and systemic DXd exposure was lo...
20 CitationsSource
Cited By0
#1Kamal S. Saini (Covance)H-Index: 17
#2Kevin Punie (Katholieke Universiteit Leuven)H-Index: 10
Last. Sherene Loi (Peter MacCallum Cancer Centre)H-Index: 85
view all 9 authors...
INTRODUCTION : Advanced breast cancer (aBC) remains incurable and the quest for more effective systemic anticancer agents continues. Promising results have led to the FDA approval of three antibody-drug conjugates (ADCs) and two immune checkpoint inhibitors (ICIs) to date for patients with aBC. AREAS COVERED : With the anticipated emergence of newer ADCs and ICIs for patients with several subtypes of breast cancer, and given their potential synergy, their use in combination is of clinical intere...
1 CitationsSource
#1Kohei ShitaraH-Index: 46
#2Eishi Baba (Kyushu University)H-Index: 28
Last. Kensei Yamaguchi (JFCR: Japanese Foundation for Cancer Research)H-Index: 35
view all 6 authors...
Approximately 12-15% of gastric cancers (GCs) are human epidermal growth factor receptor-2 (HER2)-positive (HER2 immunohistochemistry 3 + or 2 + /in situ hybridization + [ERBB2/CEP17 ≥ 2.0]). While the anti-HER2 monoclonal antibody trastuzumab, in combination with chemotherapy, is the standard treatment for HER2-positive GC, other HER2-targeted therapies have not demonstrated survival benefits in patients with GC, despite showing efficacy in patients with HER2-positive breast cancer. This indica...